OverviewSuggest Edit

ADC Therapeutics is a biotechnology company that focuses on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and haematological cancers. The company employs monoclonal antibodies specific to particular tumour antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine-based warheads to selectively kill cancer cells.
TypePrivate
Founded2010
HQEpalinges, CH
Websiteadctherapeutics.com

Latest Updates

Employees (est.) (Oct 2019)102(-18%)
Revenue (FY, 2018)$1.1 M(-36%)

Key People/Management at ADC Therapeutics

Chris Martin

Chris Martin

Chief Executive Officer, Director
Michael Forer

Michael Forer

Vice Chairman, Executive Vice President & Chief Financial Officer
Jay Feingold

Jay Feingold

Senior Vice President, Chief Medical Officer & Head of Oncology
Dulce Gonçalves

Dulce Gonçalves

Head Legal, Deputy General Counsel
Stéphane Henchoz

Stéphane Henchoz

Director of Finance
Richard Onyett

Richard Onyett

Vice President of Business Development
Show more

ADC Therapeutics Office Locations

ADC Therapeutics has offices in Epalinges, New Providence, San Mateo and Greater London
Epalinges, CH (HQ)
3B Route de la Corniche
Greater London, GB
Queen Mary Innovation Centre 42 New Rd
New Providence, US
430 Mountain Ave
San Mateo, US
1510 Fashion Island Blvd #205
Show all (4)

ADC Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2010

ADC Therapeutics total Funding

$526 m

ADC Therapeutics latest funding size

$25 m

Time since last funding

3 months ago

ADC Therapeutics investors

ADC Therapeutics's latest funding round in July 2019 was reported to be $25 m. In total, ADC Therapeutics has raised $526 m
Show all financial metrics

ADC Therapeutics Revenue

ADC Therapeutics's revenue was reported to be $1.14 m in FY, 2018 which is a 36.8% decrease from the previous period.
USD

Revenue (FY, 2018)

1.1m

Revenue growth (FY, 2017 - FY, 2018), %

(36.8%)

Net income (FY, 2018)

(123.1m)

EBIT (FY, 2018)

125.9m

Cash (31-Dec-2018)

138.8m
USDFY, 2017FY, 2018

Revenue

1.8m1.1m

Revenue growth, %

(37%)

General and administrative expense

7.9m8.8m

R&D expense

85.5m118.3m
USDFY, 2017FY, 2018

Cash

262.8m138.8m

Accounts Receivable

1.1m192.0k

Current Assets

265.2m142.1m

PP&E

1.1m1.5m
USDFY, 2017FY, 2018

Net Income

(89.9m)(123.1m)

Depreciation and Amortization

341.0k740.0k

Accounts Payable

5.5m(858.0k)

Cash From Operating Activities

(74.9m)(121.4m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

ADC Therapeutics Operating Metrics

Sep, 2019

Clinical Phase Products (Hematology)

3

Clinical Phase Products (Solid Tumor)

2

Preclinical Phase Products (Solid Tumor)

2
Show all operating metrics

ADC Therapeutics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
ADC Therapeutics America, Inc.
ADC Therapeutics (UK) Ltd

ADC Therapeutics Online and Social Media Presence

Embed Graph

ADC Therapeutics News and Updates

ADC Therapeutics to offer 8.1 million shares in planned IPO, priced at $23 to $26 each

ADC Therapeutics SA set terms for its planned initial public offering on Monday, saying in a regulatory filing that it expects to offer 8.1 million shares priced at $23 to $26 each. The clinical-stage, oncology-focused biotech has applied to list on the New York Stock Exchange, under the ticker sym…

AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

Chronic Lymphocytic Leukemia Treatment 2018 Global Market Key Players – 4SC, AbbVie, ACEA Biosciences, ADC Therapeutics, Aeglea BioTherapeutics – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Chronic Lymphocytic Leukemia Treatment Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

ADC Therapeutics Frequently Asked Questions

  • When was ADC Therapeutics founded?

    ADC Therapeutics was founded in 2010.

  • Who are ADC Therapeutics key executives?

    ADC Therapeutics's key executives are Chris Martin, Michael Forer and Jay Feingold.

  • How many employees does ADC Therapeutics have?

    ADC Therapeutics has 102 employees.

  • What is ADC Therapeutics revenue?

    Latest ADC Therapeutics annual revenue is $1.1 m.

  • What is ADC Therapeutics revenue per employee?

    Latest ADC Therapeutics revenue per employee is $11.2 k.

  • Who are ADC Therapeutics competitors?

    Competitors of ADC Therapeutics include Araris Biotech, Ajinomoto Althea and Syndesi Therapeutics.

  • Where is ADC Therapeutics headquarters?

    ADC Therapeutics headquarters is located at 3B Route de la Corniche, Epalinges.

  • Where are ADC Therapeutics offices?

    ADC Therapeutics has offices in Epalinges, New Providence, San Mateo and Greater London.

  • How many offices does ADC Therapeutics have?

    ADC Therapeutics has 4 offices.